|
 |
Wanda Reynolds's
Pub Med References
Wang Z, Nicholls S, Rodriquez R, Kummu, Horkko S, Barnard J, Reynolds
W, Topol E, DiDonato J, Hazen S. (2007) Protein Carbamylation as a
mechanism linking inflammation, smoking, uremia and atherogenesis.
Nature Medicine. Nat.Med.
10:1176-84 2007.
Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF
Transgenic
mice express human
MPO -463G/A alleles at atherosclerosis lesions, developing hyperlipidemia
and obesity in -463G males.
J Lipid Res. 2006 Jul;47(7):1366-77
Reynolds WF, Kumar AP, Piedrafita FJ
The human myeloperoxidase
gene is regulated by LXR
and PPARa ligands.
Biochem Biophys Res Commun, 2006 349:846.854
Reynolds WF, Sermet-Gaudelus I, Gausson V, Feuillet M-N, Bonnefont
J-P, Lenoir G, Descamps-
Latscha B, Witko-Sarsat V
Myeloperoxidase promoter polymorphism
-463G is associated with
more severe clinical expression of cystic fibrosis pulmonary disease.
Mediat of Inflamm, 2006:1-8
Kumar AP, Reynolds WF.
Statins downregulate myeloperoxidase gene expression in macrophages.
Biochem Biophys Res Commun. 2005 Jun 3;331(2):442-51.
Kumar AP, Ryan C, Cordy V, Reynolds WF. Inducible nitric
oxide synthase expression is inhibited by myeloperoxidase.
Nitric Oxide. 2005 Aug;13(1):42-53.
Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA.
Myeloperoxidase polymorphism related to cardiovascular events in coronary
artery disease.
Am J Med. 2004 Mar 15;116(6):429-30. No abstract available.
Kumar AP, Piedrafita FJ, Reynolds WF.
Peroxisome proliferator-activated receptor gamma ligands regulate
myeloperoxidase expression in macrophages by an estrogen-dependent
mechanism involving
the -463GA promoter polymorphism.
J Biol Chem. 2004 Feb 27;279(9):8300-15. Reynolds WF, Patel K, Pianko S, Blatt LM, Nicholas JJ, McHutchison
JG.
A genotypic association implicates myeloperoxidase in the progression
of hepatic fibrosis in chronic hepatitis C virus infection.
Genes
Immun. 2002 Sep;3(6):345-9. Reynolds WF, Stegeman CA, Tervaert JW.
-463 G/A myeloperoxidase promoter polymorphism is associated with clinical
manifestations and the course of disease in MPO-ANCA-associated vasculitis.
Clin
Immunol. 2002 May;103(2):154-60. Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, Gunn
GB, Whitehead LW, Wu X.
A myeloperoxidase polymorphism associated with reduced risk of lung
cancer.
Lung Cancer, 2002, 37:35-40. Brennan M, Gaur A, Pahuja A, Lusis AJ, Reynolds WF.
Mice lacking myeloperoxidase are more susceptible to experimental
autoimmune encephalomyelitis.
J Neuroimmunol, 2001, 112:97-105. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi
S, Lehtovirta M, Alafuzoff I, Soininen H.
MPO and APOEepsilon4 polymorphisms interact to increase risk for
AD in Finnish males.
Neurology, 2000, 55, 1284-1290. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg
H, Maki RA, Masliah E.
Myeloperoxidase polymorphism is associated with gender specific
risk for Alzheimer's disease.
Exp Neurol. 1999 Jan;155(1):31-41. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V.
An allelic association implicates myeloperoxidase in the etiology
of acute promyelocytic leukemia.
Blood. 1997 Oct 1;90(7):2730-7. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino
T, Smith RA, Nelson JR, Reynolds WF.
Immunohistochemical and genetic evidence of myeloperoxidase
involvement in multiple sclerosis.
J Neuroimmunol. 1997 Sep;78(1-2):97-107. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl
M, Reynolds WF.
An Alu element in the myeloperoxidase promoter contains a
composite SP1-thyroid hormone-retinoic acid response element.
J Biol Chem. 1996 Jun 14;271(24):14412-20. Vansant G, Reynolds WF.
The consensus sequence of a major Alu subfamily contains
a functional retinoic acid response element.
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8229-33.
|
